Carbonic-anhydrase-inhibitor pharmacology for altitude sickness prevention
Acetazolamide (brand name Diamox) is a sulfonamide-derived carbonic anhydrase inhibitor, originally developed as a diuretic and glaucoma treatment, that has become the mainstay pharmacologic prophylaxis against acute mountain sickness (AMS). Taken orally before and during ascent, it works not by blocking hypoxia's effects directly but by pre-emptively nudging the body's own acid-base chemistry toward the state it would eventually reach through days of natural acclimatization.
Acetazolamide is rapidly and almost completely absorbed after oral dosing, with peak plasma concentrations reached within 1–3 hours. But its therapeutic effect on renal bicarbonate handling needs to build over multiple dosing intervals to produce a stable, mild metabolic acidosis — the actual driver of the ventilatory benefit.
Because the drug is excreted unchanged by the kidneys (it is not metabolized), a steady dosing rhythm of every 12 hours maintains a fairly constant inhibitory effect on carbonic anhydrase throughout the day and night, which is precisely when the effect matters most — nocturnal hypoventilation is the period of greatest desaturation risk at altitude.
This is why guidelines recommend starting acetazolamide before symptoms appear, not after: it is a pre-acclimatization tool, not a rescue treatment for established AMS (though it is sometimes used adjunctively at treatment doses once symptoms exist).
The most widely used regimen is 125 mg by mouth twice daily, started 1–2 days before ascent and continued through the highest sleeping altitude, then typically for 2–3 days after reaching that altitude or until descent begins.
For higher-risk situations — very rapid ascent profiles, high sleeping altitudes reached in a single push, or a strong prior history of AMS — some clinicians step up to 250 mg twice daily, accepting a higher side-effect burden for a modest additional efficacy gain (quantified in Stage 5).
Extended-release 500 mg once-daily formulations exist in some markets and offer similar total daily exposure with simpler adherence, though the immediate-release twice-daily regimen remains the most extensively studied in altitude-medicine trials.
Wilderness Medical Society clinical practice guidelines recommend 125 mg acetazolamide twice daily, beginning the day before ascent, as first-line prophylaxis for travelers with a history of AMS or those ascending rapidly to sleeping altitudes above roughly 2,750 m (9,000 ft).
Not every traveler to altitude needs medication — gradual ascent with built-in acclimatization days remains the safest and most physiologic strategy. Acetazolamide is reserved for situations where gradual ascent is impractical: rapid trekking itineraries, high-altitude air travel directly to elevation, climbers with a documented prior AMS history, and those with occupational or expedition schedules that force fast elevation gain.
Contraindications and cautions include severe sulfonamide allergy history (addressed in Stage 5), significant renal or hepatic impairment, and pregnancy (relative contraindication). For most healthy adults, acetazolamide prophylaxis is well tolerated and is the best-studied pharmacologic option available.
Carbonic anhydrase is a zinc-metalloenzyme that catalyzes the reversible hydration of carbon dioxide: CO2 + H2O ↔ H2CO3 ↔ H+ + HCO3-. In the kidney's proximal convoluted tubule, this reaction is the engine that lets the body reclaim nearly all of the bicarbonate filtered by the glomerulus. Acetazolamide binds the enzyme's active-site zinc and shuts this engine down, with direct downstream consequences for whole-body acid-base balance.
Every day the kidneys filter roughly 4,300 mEq of bicarbonate at the glomerulus — far too much to simply excrete without derailing systemic pH. Proximal tubule cells reclaim about 80–90% of this filtered load using a coordinated system: an apical Na+/H+ exchanger secretes H+ into the tubule lumen, where luminal (membrane-bound, CA-IV) carbonic anhydrase combines it with filtered HCO3- to form H2CO3, which dehydrates to CO2 and water and freely diffuses back into the cell.
Inside the cell, cytoplasmic carbonic anhydrase (CA-II) reverses the reaction — combining CO2 and water back into H2CO3, which dissociates into a new H+ (recycled to the lumen) and a new HCO3- that exits across the basolateral membrane into the peritubular capillary blood. The enzyme therefore appears twice in the same reclamation loop, at both the luminal brush border and inside the cytoplasm.
As a sulfonamide, acetazolamide's sulfamoyl group coordinates directly with the catalytic zinc ion buried in carbonic anhydrase's active site, competitively and reversibly blocking substrate access. Because acetazolamide inhibits both the luminal (CA-IV) and cytoplasmic (CA-II) isoenzymes in proximal tubule cells, the entire bicarbonate-reclamation loop stalls at once — less H+ is secreted, less filtered HCO3- is converted and reabsorbed, and the unreclaimed bicarbonate simply continues down the nephron and is excreted in the urine (bicarbonaturia), carrying sodium and water with it (the drug's original diuretic effect).
The practical consequence for systemic physiology is a mild, self-limited normal-anion-gap metabolic acidosis: plasma bicarbonate falls modestly, blood pH drifts slightly acidic, and urine becomes markedly alkaline as it fills with the excreted bicarbonate.
Even a modest reduction in tubular bicarbonate reabsorption is physiologically potent: plasma HCO3- typically falls by 2–4 mEq/L within about 24 hours of starting therapy — enough to meaningfully shift acid-base balance without producing dangerous or even clinically apparent acidosis.
This induced acidosis is not a side effect to be minimized — it is the entire therapeutic mechanism. Unlike the body's slow natural renal compensation for altitude-induced respiratory alkalosis (which unfolds over 3–5 days as the kidneys gradually excrete bicarbonate in response to hyperventilation), acetazolamide creates the bicarbonate deficit directly and immediately, independent of any ventilatory trigger.
The effect plateaus once a new, lower steady-state plasma bicarbonate is reached — typically within a day or two of starting a stable dose — which is exactly why guidelines recommend beginning the drug before ascent rather than only after symptoms appear.
The mild metabolic acidosis created in the kidney does not stay local — it is sensed centrally. Chemoreceptors in the medulla oblongata continuously monitor the acid-base status of the cerebrospinal fluid and blood, and a fall in pH is a powerful stimulus to breathe more. Acetazolamide exploits this reflex to raise ventilation pharmacologically, achieving in about a day what unassisted acclimatization takes several days to accomplish.
At altitude, hypoxia itself stimulates peripheral chemoreceptors (carotid bodies) to increase ventilation — the hypoxic ventilatory response. But this hyperventilation blows off CO2, causing a respiratory alkalosis that actually blunts further increases in breathing, partially braking the very response that is helping. Over 3–5 days, the kidneys slowly correct this alkalosis by excreting bicarbonate, which removes the brake and allows ventilation to climb further — this is the core of natural altitude acclimatization.
Acetazolamide short-circuits this multi-day waiting process: by directly forcing renal bicarbonate loss from day one, it removes the same "brake" immediately, rather than waiting for the slow feedback loop triggered by hypoxia-driven hyperventilation to run its course.
Central chemoreceptors near the medulla's ventral surface respond primarily to the [H+] of the cerebrospinal fluid, which closely tracks arterial PCO2 and, over time, systemic acid-base status. Peripheral chemoreceptors in the carotid bodies respond to arterial PO2 as well as pH and PCO2, providing the fast, breath-by-breath drive that dominates the initial hypoxic response.
Acetazolamide's systemic acidosis lowers blood (and eventually CSF) pH, which is interpreted by both sensor systems as a signal to increase minute ventilation — raising both the rate and depth of breathing, even at a given level of oxygen availability.
In classic altitude-physiology trials, acetazolamide 250 mg twice daily increased resting minute ventilation by roughly a third and measurably raised arterial oxygen saturation within about 24 hours — well before the body's own renal compensation would have produced a comparable effect unaided.
Increased alveolar ventilation raises alveolar PO2 and lowers alveolar (and arterial) PCO2. The result is a rightward, more favorable shift in blood gases: arterial PO2 rises by roughly 3–8 mmHg and PCO2 falls by roughly 3–5 mmHg compared with an unmedicated ascent at the same altitude.
Because the metabolic acidosis and the respiratory response move blood pH in opposite directions, net arterial pH typically stays close to normal — but at a new equilibrium defined by a higher ventilatory set point and lower bicarbonate, which is functionally identical to where natural acclimatization eventually arrives.
Sleep is the most dangerous window for altitude hypoxia. Loss of the wakefulness drive to breathe allows ventilation to fall, oxygen saturation to dip, and — in many unacclimatized people — a cyclical pattern of apnea, desaturation, and arousal called periodic (Cheyne-Stokes) breathing to take over. By raising baseline ventilatory drive around the clock, acetazolamide smooths this pattern, keeps nocturnal SpO2 higher, and measurably reduces next-morning AMS symptom scores.
During sleep, especially non-REM sleep, the wakefulness stimulus to breathe disappears and ventilatory control depends almost entirely on chemoreceptor feedback. At altitude, this can become unstable: as PCO2 falls below an "apneic threshold," breathing pauses; oxygen saturation drops during the pause; the resulting hypoxic/hypercapnic stimulus triggers an arousal and a burst of hyperpnea; PCO2 overshoots low again; and the cycle repeats.
This periodic breathing pattern can dominate a large fraction of the night in unacclimatized sleepers at altitudes above roughly 2,500–3,000 m, producing repeated oxygen desaturation events that are believed to contribute disproportionately to next-day AMS symptoms.
By lowering baseline plasma bicarbonate and shifting the whole ventilatory control system toward a higher set point, acetazolamide narrows the gap between the normal breathing PCO2 and the lower apneic threshold PCO2 at which breathing pauses are triggered. A narrower gap means ventilation is far less likely to dip low enough to cross that apnea threshold in the first place.
The practical result seen on polysomnography is fewer, shorter apnea/hypopnea events, more continuous breathing through the night, and a higher average and nadir oxygen saturation — even though the person is sleeping at the same physical altitude.
Polysomnographic studies of unacclimatized sleepers at altitude have found periodic breathing occupying more than half of total sleep time without prophylaxis, falling to well under 20% of the night with acetazolamide, alongside a 5–10 percentage-point improvement in nocturnal SpO2 nadir.
Because AMS symptoms — headache, nausea, fatigue, dizziness, poor sleep — correlate strongly with the severity of nocturnal desaturation, stabilizing overnight oxygenation translates directly into lower next-morning Lake Louise AMS scores in treated individuals compared with placebo.
Trekkers and climbers on acetazolamide commonly report subjectively better sleep quality as well, independent of the objective saturation data, likely reflecting fewer arousal-related awakenings — an important secondary benefit for next-day performance and decision-making at altitude.
Like most drugs, acetazolamide does not deliver benefit in direct proportion to dose forever. Clinical trials describe a classic saturating dose-response curve for AMS prevention: efficacy rises steeply over the low-to-moderate dose range and then plateaus, while the burden of bothersome (though rarely dangerous) side effects continues to climb roughly linearly with dose — defining a practical sweet spot rather than a "more is better" relationship.
Meta-analyses of placebo-controlled trials, including a widely cited Cochrane review, find acetazolamide reduces the relative risk of developing AMS by roughly 50–75% depending on dose and ascent profile, compared with no prophylaxis. Critically, the jump from 125 mg to 250 mg twice daily produces only a modest additional efficacy gain — the dose-response curve is already bending toward its ceiling by the standard 125 mg BID regimen for most travelers.
This is why 125 mg BID remains the default recommendation for most people: it captures the large majority of the achievable benefit while minimizing exposure to dose-dependent side effects.
The most characteristic side effect is peripheral paresthesias — tingling or "pins and needles" sensations in the fingers, toes, and around the lips — caused by the same systemic carbonic anhydrase inhibition acting in peripheral nerves. It is common, dose-dependent, harmless, and fully reversible on stopping the drug.
Other frequent effects include a mild diuretic/polyuria effect (increased urination, especially early in treatment), and a distinctive dysgeusia — an unpleasant flat or metallic taste specifically for carbonated beverages, sometimes nicknamed the "Diamox fizz" effect, caused by carbonic anhydrase inhibition in taste bud cells altering carbonation perception.
In trials comparing regimens, paresthesias were reported in roughly half of patients at 125 mg twice daily, rising to as many as ~90% at 250 mg twice daily — annoying and sometimes treatment-limiting for sensitive individuals, but not a marker of harm, and fully reversible after discontinuation.
Acetazolamide is chemically a sulfonamide, which historically raised concern about cross-reactivity in patients with a documented "sulfa allergy." Contemporary pharmacologic review, however, indicates that cross-reactivity between non-antibacterial sulfonamides (like acetazolamide) and antibacterial sulfonamides (like sulfamethoxazole) is rare and was likely overstated in older literature, since the immunogenic mechanisms differ.
Still, patients with a history of severe reactions (e.g., Stevens-Johnson syndrome) to any sulfonamide are generally advised to avoid acetazolamide and use an alternative, and any new patient should be started under appropriate medical guidance.
Dexamethasone, a corticosteroid, is the principal pharmacologic alternative for AMS prophylaxis in people who cannot take or do not tolerate acetazolamide. It works through an entirely different mechanism — reducing cerebral and systemic inflammatory/vascular permeability responses to hypoxia rather than modulating acid-base chemistry — and is effective for both prevention and treatment, but carries its own side-effect profile (mood changes, hyperglycemia, rebound symptoms on stopping) that generally makes it less suitable for extended prophylactic use.
For anyone, the single most effective and side-effect-free strategy remains a gradual ascent profile that gives the body time for genuine physiologic acclimatization — pharmacologic prophylaxis is best viewed as a complement to sensible ascent planning, not a substitute for it.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Acetazolamide 125 mg BID | ~50–60% relative risk reduction | Mild bicarbonaturic metabolic acidosis, moderate ventilatory stimulation | Best-studied, favorable side-effect balance; default first-line choice |
| Acetazolamide 250 mg BID | ~65–75% relative risk reduction | Larger bicarbonate loss, stronger ventilatory stimulation | Reserved for higher-risk/rapid ascents; more paresthesias, polyuria, dysgeusia |
| Dexamethasone | Comparable efficacy to acetazolamide | Anti-inflammatory / vascular permeability effect, not acid-base mediated | Alternative for sulfonamide-intolerant patients; not ideal for long prophylactic courses |
| No prophylaxis (gradual ascent only) | Baseline AMS incidence, highly ascent-rate dependent | Relies solely on natural multi-day renal/ventilatory acclimatization | No drug side effects; requires conservative, time-consuming ascent schedule |